Veracyte, Inc. (VCYT) company profile
Close on Nov 17, 2026Market cap $1.95BP/E 17.3Yield –
About Veracyte
Services-Medical Laboratories, SIC 8071
Veracyte is a molecular diagnostics company that develops and performs clinical genomic tests to assist in diagnosing and treating various forms of cancer. Its primary commercial offerings include Decipher tests for prostate and bladder cancers, the Afirma classifier for thyroid nodules, and the Prosigna assay for breast cancer. The business operates through laboratory developed tests analyzed in centralized facilities as well as distributed in vitro diagnostic test kits. Its customers include physicians, endocrinologists, oncologists, hospitals, independent laboratories, and biopharmaceutical partners.
In the United States, the company operates three clinical reference laboratories located in South San Francisco, California; San Diego, California; and Austin, Texas. Outside the United States, it distributes test kits across Europe, the Middle East, Asia Pacific, Latin America, and Canada. Its diagnostic products receive reimbursement across numerous countries, including Germany, France, Spain, Italy, Canada, and Israel. The provided text notes these operating facilities but does not identify a corporate headquarters.
Summary of the business section of Veracyte's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Veracyte, Inc.
- Headquarters
- South San Francisco, CA
- Address
- 6000 Shoreline Court, Suite 300 94080
- Phone
- (650) 243-6300
- Website
- veracyte.com
- Employees
- 755, Dec 31, 2025
- Industry
- Services-Medical Laboratories
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Diego, California
Stock & identifiers
- Ticker
- VCYT
- Exchange
- Nasdaq
- IPO date
- Oct 30, 2013
- Shares outstanding
- 80M, Jul 27, 2026
- Public float
- $1.70B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1384101
- CUSIP
- 92337F107
- ISIN
- US92337F1075
- FIGI
- BBG001J2M542
- Share class FIGI
- BBG001TSQWW0
- LEI
- 529900ESWZRHXOW27Z37
- EIN
- 20-5455398
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Marc Stapley | Chief Executive Officer, Director | 432,073 |
| Jonathan Wygant | VP, Chief Accounting Officer | 41,920 |
| John Leite | Global Chief Commercial Off | 124,329 |
| Phillip G. Febbo | Chief Scientific & Med Officer | 133,048 |
| Rebecca Chambers | Chief Financial Officer | 167,200 |
| Annie McGuire | EVP, General Counsel | 132,260 |
| Kevin Richard Haas | Chief Dev and Tech Officer | 44,221 |
| Jens Holstein | Director | 27,471 |
| Karin Eastham | Director | 11,488 |
| Muna Bhanji | Director | 40,854 |
| Robert S. Epstein | Director | 57,718 |
| Evan/ Fa Jones | Director | 34,634 |
| David Brent Shafer | Director | 31,100 |
| Eliav Barr | Director | 56,461 |
| Thomas F. Miller | Director | 31,100 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $7.42M | $9.61M | $2.84M | $86 | $125 |
| FY2024 | $6.82M | $14.89M | $3.15M | $81 | $93 |
| FY2023 | $7.18M | $9.56M | $2.74M | $56 | $94 |
| FY2022 | $4.94M | $1.62M | $3.73M | $48 | $90 |
| FY2021 Anderson | $4.52M | $2.88M | $2.24M | $84 | $100 |
| FY2021 Stapley | $5.74M | $5.70M | $2.24M | $84 | $100 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Marc Stapley Chief Executive Officer | $700.00K | $5.89M | $826.00K | $5.00K | $7.42M | +9% |
| Rebecca Chambers Chief Financial Officer | $550.00K | $1.96M | $356.95K | $5.00K | $2.88M | -21% |
| Phillip Febbo Chief Scientific Officer and Chief Medical Officer | $561.00K | $1.57M | $364.09K | $5.00K | $2.50M | -10% |
| John Leite Global Chief Commercial Officer | $510.30K | $2.36M | $331.19K | $5.00K | $3.20M | +4% |
| Annie McGuire General Counsel and Head of Market Access | $500.00K | $1.96M | $324.50K | $5.00K | $2.79M | -10% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 30, 2013
- Securities offered
- 5,000,000
- Exchange
- Nasdaq
- First trading day
- Oct 30, 2013
- First-day close
- $13.25
- Lock-up ends (est.)
- Apr 28, 2014
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 755 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 14, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 6, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 3, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 15, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 3, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 17, 2014 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 10, 2014 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Oct 30, 2013 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 28, 2013 | Listing | Registration of securities on an exchange (Form 8-A) |
| Feb 27, 2008 | Name change | Name changed from CALDEROME INC to Veracyte, Inc. |
See a number that looks wrong?